Trial Profile
TR study of "A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer (BRAVERY study)"
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Sep 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- Acronyms BRAVERY TR
- 24 Sep 2021 Status changed from active, no longer recruiting to completed.
- 08 Jun 2021 Results of translational research of the BRAVERY study presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 11 Nov 2019 Status changed from recruiting to active, no longer recruiting.